NCT02209844已完成1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (2.5 mg to 1200 mg) of BI 44847 as Powder in the Bottle Reconstituted With 0.2% Natrosol Solution Administered to Healthy Male Subjects. A Randomised, Placebo-controlled (Within Dose Groups) and Double-blinded Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 72
- 主要终点
- Number of patients with clinically significant findings in ECG
研究概览
简要总结
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 44847
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (BP, HR), 12-lead ECG, clinical laboratory tests
- •Age ≥ 18 and Age ≤ 50 years
- •BMI ≥ 18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
排除标准
- •Any finding of the medical examination (including BP, pulse rate and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (more than 60 g/day)
- •Blood donation (more than 100 mL) within four weeks prior to administration or during the trial
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of study centre
- •Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval > 120 ms. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 450 ms or QT> 500 ms).
- •A history of additional risk factors for Torsade des Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- •The use of concomitant medications that prolong the QT/QTc interval
- •Elevated urinary glucose levels at screening (> 15 mg/dl)
研究组 & 干预措施
BI 44847 powder
Experimental
single rising dose reconstituted with natrosol solution
干预措施: BI 44847 (Drug)
Placebo
Placebo Comparator
reconstituted with natrosol solution
干预措施: Placebo (Drug)
结局指标
主要结局
Number of patients with clinically significant findings in ECG
时间窗: up to day 12
Number of patients with clinically significant laboratory findings
时间窗: up to day 12
Assessment of tolerability by the investigator on a 4-point scale
时间窗: up to day 12
Number of patients with adverse events
时间窗: up to day 12
Number of patients with clinically significant findings in vital signs (blood pressure, pulse rate)
时间窗: up to day 12
次要结局
- Cmax (maximum concentration of the analyte in plasma)(up to 96 hours after drug administration)
- tmax (time from dosing to maximum concentration)(up to 96 hours after drug administration)
- AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 96 hours after drug administration)
- %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)(up to 96 hours after drug administration)
- AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 96 hours after drug administration)
- λz (terminal rate constant in plasma)(up to 96 hours after drug administration)
- t1/2 (terminal half-life of the analyte in plasma)(up to 96 hours after drug administration)
- MRTpo (mean residence time of the analyte in the body after oral administration)(up to 96 hours after drug administration)
- CL/F (total clearance of the analyte in the plasma after extravascular administration)(up to 96 hours after drug administration)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 96 hours after drug administration)
- Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)(up to 72 hours after drug administration)
- fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)(up to 72 hours after drug administration)
- CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)(up to 72 hours after drug administration)
- Area under the plasma glucose concentration time curve(up to 96 hours after drug administration)
- Total amount of glucose excreted in urine(up to 72 hours after drug administration)
- Maximum glucose concentration in plasma(up to 96 hours after drug administration)
- Maximum glucose concentration in urine(up to 72 hours after drug administration)
研究者
相似试验
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT02211963Boehringer Ingelheim48
已完成
1 期
4 Weeks Treatment of Type II Diabetic Patients With BI 44847Diabetes Mellitus, Type 2NCT00558909Boehringer Ingelheim80
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Administered to Healthy Male SubjectsHealthyNCT02211924Boehringer Ingelheim48
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female VolunteersHealthyNCT02171806Boehringer Ingelheim47
已完成
1 期
To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male VolunteersHealthyNCT02093819Boehringer Ingelheim60